Sunny Pharmtech Inc. (TPEX:6676)
Taiwan · Delayed Price · Currency is TWD 12.35
+0.20 (1.65%)
Aug 26, 2026, 1:49 PM CST
Sunny Pharmtech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 233.36 | 253.01 | 418.01 | 428.83 | 359.59 | 241 | |
Revenue Growth | -19.58% | -39.47% | -2.52% | 19.26% | 49.21% | -42.61% |
Cost of Revenue | 196.4 | 179.87 | 191.61 | 143.3 | 152.88 | 125.25 |
Gross Profit | 36.96 | 73.14 | 226.4 | 285.53 | 206.71 | 115.75 |
Selling, General & Admin | 154.73 | 163.81 | 170.11 | 148.76 | 138.45 | 120.39 |
Research & Development | 232.32 | 226.86 | 219.28 | 208.87 | 255.88 | 171.37 |
Operating Expenses | 387.05 | 390.66 | 389.39 | 357.62 | 394.33 | 291.75 |
Operating Income | -350.09 | -317.53 | -162.99 | -72.1 | -187.62 | -176 |
Interest Expense | -11.49 | -10.36 | -9.07 | -11.24 | -4.59 | -5.62 |
Interest & Investment Income | 1.66 | 2.12 | 4.54 | 5.73 | 1.38 | 0.36 |
Currency Exchange Gain (Loss) | -3.4 | -3.4 | 10.74 | 12.23 | 16.15 | -3.18 |
Other Non Operating Income (Expenses) | 11.26 | 0.19 | 0.7 | 3.38 | 4.53 | 3.31 |
EBT Excluding Unusual Items | -352.06 | -328.97 | -156.08 | -62 | -170.15 | -181.14 |
Gain (Loss) on Sale of Investments | 27.06 | 27.06 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.13 | -0.13 | 0.08 | -0.08 | -0.09 | - |
Asset Writedown | - | - | - | -1.24 | - | - |
Other Unusual Items | - | - | - | - | - | 4.48 |
Pretax Income | -325.13 | -302.05 | -156 | -63.32 | -170.24 | -174.79 |
Net Income | -325.13 | -302.05 | -156 | -63.32 | -170.24 | -174.79 |
Net Income to Common | -325.13 | -302.05 | -156 | -63.32 | -170.24 | -174.79 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 152 | 149 | 149 | 143 | 139 | 134 |
Shares Outstanding (Diluted) | 152 | 149 | 149 | 143 | 139 | 134 |
Shares Change | 2.33% | 0.22% | 4.20% | 3.04% | 3.60% | 3.29% |
EPS (Basic) | -2.14 | -2.03 | -1.05 | -0.44 | -1.23 | -1.31 |
EPS (Diluted) | -2.14 | -2.03 | -1.05 | -0.44 | -1.23 | -1.31 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -186.71 | -188.32 | -82.81 | -105.88 | -152.3 | -193.31 |
Free Cash Flow Per Share | -1.23 | -1.26 | -0.56 | -0.74 | -1.10 | -1.45 |
Gross Margin | 15.84% | 28.91% | 54.16% | 66.58% | 57.48% | 48.03% |
Operating Margin | -150.02% | -125.50% | -38.99% | -16.81% | -52.18% | -73.03% |
Profit Margin | -139.33% | -119.38% | -37.32% | -14.77% | -47.34% | -72.53% |
Free Cash Flow Margin | -80.01% | -74.43% | -19.81% | -24.69% | -42.35% | -80.21% |
EBITDA | -231.6 | -198.79 | -48.45 | 41.34 | -83.09 | -76.24 |
EBITDA Margin | -99.25% | -78.57% | -11.59% | 9.64% | -23.11% | -31.64% |
D&A For EBITDA | 118.49 | 118.74 | 114.54 | 113.44 | 104.53 | 99.76 |
EBIT | -350.09 | -317.53 | -162.99 | -72.1 | -187.62 | -176 |
EBIT Margin | -150.02% | -125.50% | -38.99% | -16.81% | -52.18% | -73.03% |